Tiziana Life Sciences is trading at $0.65, with a -6.39% change as investors weigh Phase 2a results in which the 100-µg dose did not beat placebo. - The 50-µg dose reduced microglial activation; coverage noted uncertainty about the development path. - The company announced positive topline results on November 2, but dose-specific efficacy appears to concern investors. - XBI is up 2.13%, suggesting the decline is company-specific rather than a broader biotech move.